Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5814639 | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(8 years ago) | |
US5914331 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(6 years ago) | |
US5922695 | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(6 years ago) | |
US5935946 | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jul, 2017
(6 years ago) | |
US5977089 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
US6703396 | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
US7176220 | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Aug, 2026
(2 years from now) | |
US7635704 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(2 years from now) | |
US8981103 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(2 years from now) | |
US8148374 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5814639 (Pediatric) | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(8 years ago) | |
US6043230 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
US5914331 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(6 years ago) | |
US5977089 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
US6043230 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
US5935946 (Pediatric) | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jan, 2018
(6 years ago) | |
US5922695 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(6 years ago) | |
US6642245 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
US6642245 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(2 years ago) | |
US6703396 (Pediatric) | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(2 years ago) | |
US8592397 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
US9744181 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
US8716264 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
US9457036 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
US8716264 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jul, 2024
(2 months from now) | |
US7176220 (Pediatric) | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(2 years from now) | |
US7635704 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(2 years from now) | |
US8981103 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(2 years from now) | |
US9891239 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
US8148374 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
US9891239 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
US8633219 | GILEAD SCIENCES INC | Combination therapy |
Apr, 2030
(6 years from now) | |
US8633219 (Pediatric) | GILEAD SCIENCES INC | Combination therapy |
Oct, 2030
(6 years from now) | |
US10039718 | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
US10039718 (Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(8 years from now) |
Stribild is owned by Gilead Sciences Inc.
Stribild contains Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Disoproxil Fumarate.
Stribild has a total of 35 drug patents out of which 20 drug patents have expired.
Expired drug patents of Stribild are:
Stribild was authorised for market use on 27 August, 2012.
Stribild is available in tablet;oral dosage forms.
Stribild can be used as treatment of hiv infection, treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase.
Drug patent challenges can be filed against Stribild from 27 August, 2016.
The generics of Stribild are possible to be released after 06 April, 2033.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-704) | Dec 17, 2017 |
New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
New Patient Population(NPP) | Jan 27, 2020 |
New Product(NP) | Aug 27, 2015 |
NCE-1 date: 27 August, 2016
Market Authorisation Date: 27 August, 2012
Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Dosage: TABLET;ORAL